Literature DB >> 1551290

Considerations in dosage selection for third generation cephalosporins.

J H Yuk-Choi1, C H Nightingale, T W Williams.   

Abstract

Pharmacokinetic parameters of third generation cephalosporins vary widely, requiring different dosage regimens and adjustment methods for each agent. Although their antibacterial spectrum favours their usage in infections caused by aerobic Gram-negative organisms, due to their limited post-antibiotic effect against these organisms, dosage regimens should ensure that free drug concentrations at the site of infection remain above the minimum inhibitory concentration for as much of the dosage interval as possible in patients with normal host defence mechanisms and for the entire dosage interval in immunocompromised patients. Altered protein binding encountered in various disease states can affect both microbiological and pharmacokinetic properties especially for drugs with high protein binding. Since the concentrations at the site of action are often different from those in serum, a higher or lower range of dosages needs to be selected depending on the target site. Decreased renal function affects the elimination of most third generation cephalosporins, whereas the presence of hepatic disease does not generally necessitate dosage adjustment. Because of the complex age-related physiological changes in paediatric and elderly patients, dosage should be adjusted on the basis of the reported pharmacokinetic data in these populations. The usual recommended dose may or may not be optimal in a given condition depending on the complex interactions between pharmacokinetic, microbiological and other host factors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551290     DOI: 10.2165/00003088-199222020-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  92 in total

1.  Disposition of cefmetazole in healthy volunteers and patients with impaired renal function.

Authors:  C E Halstenson; D R Guay; J A Opsahl; C A Hirata; L S Olanoff; E Novak; H Ko; K S Cathcart; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

2.  Pharmacokinetics of cefotaxime in elderly patients.

Authors:  H Sugihara; K Yoneyama; H Sorimachi; T Kamo; S Imamura; N Akashi; M Yamada; T Shimizu
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Comparative penetration of cefonicid and cefazolin into the atrial appendage and pericardial fluid of patients undergoing open-heart surgery.

Authors:  M N Dudley; C H Nightingale; A D Drezner; H B Low; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

4.  Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.

Authors:  J Kneer; Y K Tam; R A Blouin; F J Frey; E Keller; C Stathakis; B Luginbuehl; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 5.  Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Ward; D M Richards
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

6.  Cefmenoxime pharmacokinetics in patients with renal insufficiency.

Authors:  R E Polk; D A Sica; T M Kerkering; B J Kline; P M Patterson; J W Baggett
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

Review 7.  Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function.

Authors:  R A Greenfield; A U Gerber; W A Craig
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

8.  Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis.

Authors:  K Konishi
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

10.  Pharmacokinetics of cefoperazone after single and multiple doses.

Authors:  S Ripa; F La Rosa; B Dainelli; U Ecari; M P Ruffilli
Journal:  Int J Clin Pharmacol Res       Date:  1986
View more
  7 in total

1.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

Review 2.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 3.  Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.

Authors:  E Strehl; F Kees
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 4.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 5.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

Review 6.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of cefotetan.

Authors:  C Martin; L Thomachot; J Albanese
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.